ChromoCure Joins Walgreens in Widespread Testing Strategy Through International Partnership and Distribution Networks
2010年5月18日 - 9:02PM
Marketwired
ChromoCure, Inc. (Genome Research Group, Inc.) (PINKSHEETS: KKUR)
continues to expand its comprehensive global Testing Strategy in
response to increased genetic research and as Walgreens begins
selling individual mail-in genetic testing kits in 7,500 of their
retail locations nationwide. Walgreens' program, together with the
worldwide increase in medical genome research, are in response to
overall medical and personal interest in chromosomal imbalance or
aneuploidy as a cause of cancer.
The Company's cancer detection technology is based on the
chromosomal theory of cancer. Research has conclusively and
irrefutably demonstrated aneuploidy a more accurate predictor of
cancer than cytological/histological analysis or genetic
marker-based diagnostics that are the only other methods in
existence today. The Company's cancer detection system locates and
measures unique genomic characteristics found in 100% of all
cancers and never found in normal cells. The Company's detection
technology has an effective 100% accuracy rate and an effective
100% specificity therefore making "false positives" and "false
negatives" theoretically impossible.
The Company recently announced the addition of Full Spectrum
ChromoSomal Scan Capability for Broad Base Cancer Progression
Assessment: Further Enhancing Detection & Progression
Monitoring. These new capabilities allow for comprehensive
DNA-index quantification and precise measurement of chromosomal
imbalance ratios and amounts; thereby providing increasing value of
vital cancer progression analysis data for the precise assessment
remission rates and protocol efficacy in the Company's expanded
Therapeutic Research initiatives worldwide.
This announcement, together with the recently announced Clinical
Testing and Trials for its landmark ChromoSomal Scanning Technology
as applied to cervical cancer and the Euro Zone launch of its
Pathologist Collaborative Research (PCR) Program in support of the
groundbreaking Project Boveri: Find the Cure Initiative, further
establishes the Company's leading role in the new era of cancer
research, detection, and therapy, as the companies leverage their
combined technologies, research knowledge and industry
relationships.
The Company possesses advanced detection and therapeutic
technology and protocols, comprised of ChromoCure's advanced
detection system and GRG's full line of therapeutic protocols and
technology; allowing for the first time real-time progression
monitoring and remission detection -- providing the world's first
cure research fully integrated system for the precise measurement
of treatment and on-demand, real-time cancer progression analysis
to monitor and determine treatment efficacy.
As a result of the recent merger and acquisition of Genome
Research Group, the combined entity possesses complementary
detection and therapeutic technology and protocols.
The Company's focus on cancer research is further underscored by
recent major clinical publications that both validate ChromoCure's
chromosomal/aneuploidy theory of cancer and establish the company's
detection approach as the forefront of both cancer detection and
research. The Mayo Clinic's recent landmark findings confirming
aneuploidy as the cause of cancer were published in the December
2009 Cancer Cell journal. This publication has spurred increased
worldwide research by a number of respected research universities
and institutions, all of which have published similar reports in
2010.
The Company believes its technologies provide the foundation for
significant advances in diagnosis, therapy and cure. Shareholders
can expect further updates on research and testing collaborations,
laboratory partnerships, and research initiatives.
Management believes these initiatives to be of significant
long-term shareholder value and furthers the Company's transition
to research, technology development, and licensing as a source of
significant long-term and recurring revenues and equity
appreciation.
About Genome Research Group, Inc. (ChromoCure,
Inc.) The Company develops and provides proprietary cancer
detection systems and related therapeutic technologies. The
Company's proprietary cancer detection system locates and measures
unique genomic characteristic found in 100% of all cancers and
never found in normal cells. The Company's detection technology has
a proven and effective accuracy of 100% for all cancers at all
stages. The Company's proprietary Therapeutic Modeling Protocols
provide statistical modeling and prediction tools for the
measurement and monitoring of cancer progression and remission. The
Company also applies its technology and knowledge to cancer cure
and therapeutics research. The Company owns proprietary cancer
detection systems and related therapeutic technologies and
proprietary techniques for non-toxic and non-invasive cancer
therapy utilizing hypothermic modulation and resonance. The
Company's proprietary CS200 Chromosomal Scanner has been proven
accurate and efficient in the measurement of the unique genomic
characteristic found in 100% of all cancers and never found in
normal cells. The Company's detection technology has an effective
accuracy of 100% for all cancers at all stages. GRG's advanced
Therapeutic Modeling and Treatment Protocols combined with its
industry and medical research collaborations validate its
leadership role in Cancer Detection, Therapy and Cure.
The Company believes its technology will become the worldwide
gold standard for cancer detection, progression measurement, and
research for both therapy and cure. The Company also applies its
technology and knowledge to cancer cure and therapeutics
research.
Safe-Harbor Statement This release
contains statements or projections regarding future performance
that is forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those projected as a result of certain risks and
uncertainties. The company's filings contain various RISK FACTORS
(and are incorporated on the Company's website "investors" section
by reference) and should be read before any investment
decision.
ChromoCure, Inc. (to be renamed Genome Research Group,
Inc.) www.ChromoCure.com www.GenomeResearchGroup.com
info@genomeresearchgroup.com Tel: +011 (44) 20 7101 9475
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 5 2024 まで 6 2024
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 6 2023 まで 6 2024